CTBP1 and angiosarcoma: Variable expression of β-ARs has been demonstrated in a broad spectrum of human vascular lesions, including angiosarcoma20,21, and this has led to the experimentation of the pharmacological inhibition of beta adrenergic receptors in angiosarcoma treatment, reporting increased progression-free and overall survival in such patients14.